| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| VEGF-C | Avitag VEC-C82E4 | Biotinylated Cynomolgus VEGF-C Protein, His,Avitag™ (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $350.00 25ug | |
| VEGF-C | Human VEGF-C / Flt4-L Protein, His Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $270.00 50ug | ||
| VEGF-C | AvitagAIDD‑Ready VEC-M82E3 | Biotinylated Mouse VEGF-C Protein, His,Avitag™ (MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $350.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| VEGF-C gene therapy (Herantis Pharma) | LX-1101; Ad-VEGF-C | Phase 2 Clinical | Herantis Pharma | Lymphedema | Details |
| IBI-333 | IBI-333 | Phase 1 Clinical | Macular Degeneration; Wet Macular Degeneration | Details |